In The News

Applied BioMath, LLC Announces Collaboration with Monte Rosa Therapeutics for Systems Pharmacology Modeling in Cereblon-based Molecular Glue Degraders

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their ongoing collaboration with Monte Rosa Therapeutics to develop a cellular systems pharmacology model for cereblon (CRBN)-based molecular glue degraders (MGDs) targeting GSPT1.

Applied BioMath, LLC Announces Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their collaboration with Celsius Therapeutics for the development of a semi-mechanistic pharmacokinetic / receptor occupancy model of a monoclonal antibody for the treat

Applied BioMath, LLC Announces Collaboration with BYOMass™ for Systems Pharmacology Modeling in Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with BYOMass, Inc. for systems pharmacology modeling in chronic diseases. BYOMass is a preclinical stage pharmaceutical company focused on the TGF-ß superfamily.

Applied BioMath, LLC Provides Systems Pharmacology Modeling in Oncology for Antengene

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, was selected by Antengene Corporation to provide systems pharmacology modeling in immuno-oncology.   Applied BioMath developed a systems pharmacology model for a PDL1/41BB bispecific antibody, ATG-101, in immuno-oncology indications.

Applied BioMath, LLC Announces Collaboration with Asher Biotherapeutics for Systems Pharmacology Modeling in Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Asher Biotherapeutics for systems pharmacology modeling in solid tumors. "We have experience that development of a biotherapeutic has the best chance of success when the R&D proc

Applied BioMath, LLC Announces that Revitope Oncology is extending its Collaboration on Systems Pharmacology Modeling in Solid Tumors

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that Revitope Oncology is extending its collaboration to develop a systems pharmacology model for Revitope's dual antigen targeting TwoGATE™ platform for solid tumor indications.

Applied BioMath, LLC Announces Collaboration with Antengene for Systems Pharmacology Modeling in Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Antengene Corporation for the development of a systems pharmacology model in immuno-oncology. Applied BioMath will develop a systems pharmacology model for a PDL1/41BB bispecific antibody, ATG-101, in immuno-oncology indications.

Applied BioMath, LLC Announces Two-Year Strategic Partnership with Xilio Therapeutics

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a two-year strategic partnership with Xilio Therapeutics.  Applied BioMath will provide a variety of services related to mathematical modeling, simulation, analysis, and visualization, which include syste

Applied BioMath, LLC Announces Collaboration with Cullinan Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Cullinan Oncology. Applied BioMath will develop a systems pharmacology model for CLN-049, a novel FLT3XCD3 bispecific antibody for Acute Myeloid Leukemia, being developed by Cullinan Florentine, a Cullinan Oncology company.